A genetic variant present in nearly half of Americans of European ancestry is linked to greater effectiveness of the smoking cessation medication bupropion (Zyban), according to research by scientists supported by the National Institute on Drug Abuse (NIDA) and the National Cancer Institute (NCI), part of the National Institutes of Health (NIH).
People with this variant were less likely than those without it to have resumed smoking six months after treatment with bupropion.
The study, published in the September issue of the journal Biological Psychiatry, is a step toward the goal of being able to tailor smoking cessation treatment to individuals based on their unique genetic make-up.
"This study is part of our ongoing commitment to develop more accurate and personalized approaches to medicine," said NIH Director Dr. Elias A. Zerhouni. "This kind of genetic research is helping us to better understand why some people respond to certain smoking cessation treatments, and others don't."
Source: National Institute on Drug Abuse
Related stories:
1/5 of British adult survivors of childhood cancer smoke despite hazards
One-fifth of British adult survivors of childhood cancers are current smokers, and nearly a third have been regular smokers at some point in their lives, according to a study in the July 29 online issue of the
Journal of the National Cancer Institute.
Gene panel predicts lung cancer survival, study finds
Researchers from four leading cancer centers have confirmed that an analysis involving a panel of genes can be used to predict which lung cancer patients will have the worst survival. The finding could one day lead to a test that would help determine who needs more aggressive treatment. The study, the largest of its kind, appears online in
Nature Medicine.
Genetic variations put youth at higher risk for lifetime of tobacco addiction
Common genetic variations affecting nicotine receptors in the nervous system can significantly increase the chance that European Americans who begin smoking by age 17 will struggle with lifelong nicotine addiction, according to researchers at the University of Utah and their colleagues at University of Wisconsin-Madison. The study, published in the July 11, 2008 issue of
PLoS Genetics, highlights the importance of public health efforts to reduce the number of youth who begin smoking.
Genes may determine which smoking cessation treatment works best
Kicking the habit may soon become easier for the nation’s 45 million smokers. For the first time, researchers have identified patterns of genes that appear to influence how well individuals respond to specific smoking cessation treatments.
Study finds it pays to be heart smart if considering hormone therapy
A research study has found that a simple blood test may indicate whether post-menopausal hormone therapies present an elevated risk of a heart attack. The study, part of the Women’s Health Initiative (WHI), sponsored by the National Heart, Lung and Blood Institute of the National Institutes of Health, was conducted in 40 centers nationwide and included 271 cases of coronary heart disease in the first four years of the trials of estrogen alone and of estrogen plus progestin.
Is it your waistline or your genes that predispose you to heart disease?
Heart disease is widely attributed to lifestyle factors such as lack of physical exercise, smoking and unhealthy weight and diet but the onset of cardiovascular disease can also come down to genetics.
Combined physical and genetic map finds cancer's 'ignition key'
Whole-organ maps that superimpose genetic information over the terrain of cancerous bladders chart the molecular journey from normal cell to invasive cancer, an international research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports online at the journal
Laboratory Investigation, a member of the Nature Publishing Group.
Researchers look at cannabinoids, genes, medicines and brain scans to find better anxiety treatments
Right now, about half of all people who take medicine for an anxiety disorder don’t get much help from it. And doctors have no definitive way to predict who will, and who won’t, benefit from each anti-anxiety prescription they write.